Close menu




MAINZ Biomed

Photo credits: pixabay.com

Commented by Armin Schulz on January 31st, 2022 | 13:31 CET

BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype

  • Biotechnology

The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.

Read

Commented by Mario Hose on January 18th, 2022 | 16:37 CET

Buy Long-Covid Stock Now? BioNTech, Cardiol, Mainz Biomed

  • Investments

The second trading day this week is characterized by a weak start to trading. In the first two hours, the German indices have clearly lost ground. The leading index DAX is currently trading at 15,776 points, down around 1.05% on the previous day. The MDAX last traded at 34,156 points (-1.38%), TecDAX at 3,498 points (-1.77%) and SDAX at 15,658 points with 1.65% in the red. In the focus of market participants today are repeatedly the shares of vaccine manufacturers, but the trend is now also to the next phase of the Corona situation, the treatment of Long-Covid.

Read